2014 Featured Speakers

  • Anderson RyanSenior Group Leader in Radiation Oncology University of Oxford

  • Sabine HovesSenior Scientist, Discovery Oncology Roche

  • Hazel JonesHead of Combination Therapies, Drug Development Office Cancer Research UK

  • Barry DaviesPrincipal Scientist AstraZeneca

Fail Smartly and Learn Fast: Develop and Harness Clinical Relevant Tumour Models

Top 5 reasons why you should have attended:

  1. Enhance your successful drug development 
  2. Learn about the latest immune-competent in vitro and in vivo models in cancer immunotherapies
  3. Improve the representation of the patient population in preclinical trails by harnessing the power of PDX models
  4. Target the tumour microenvironment with 3D modelling in drug candidate development
  5. Improve drug efficacy - explore advanced pharmaco-imaging technology that monitor pharmacokinetics in tumour models

The number one aim of this year's Tumour Model London meeting was to improve the predictability and translatability of preclinical oncology research.

If you are a preclinical oncologist, translational scientist or tumour model developer who is constantly striving to improve the predictive ability of basic oncology research and the translational success of their candidates, then you should Tumour Models London 2014 was the place to.

With an in-depth focus on cutting edge in vivo and in vitro modelling best practice, attendess discovered how the movement towards more physiologically relevant models will better mimic the tumour environment, better represent the patient population and help you prioritise the best drug candidates.

If you did miss the 2014 meeting, then we will be running a meeting in 2015 so do get in touch if you would like to be involved.